Sobi North America, the regional subsidiary of Swedish Orphan Biovitrum AB, announced on Thursday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for avatrombopag, targeting paediatric patients suffering from immune thrombocytopenia. Immune thrombocytopenia is an autoimmune disorder characterized by the reduced presence of platelets, which increases the risk of bleeding.
The decision from the FDA, under the Prescription Drug User Fee Act (PDUFA), is anticipated by July 24, 2025. In addition, the FDA has accepted Sobi's New Drug Application (NDA) for an oral suspension form of avatrombopag.
The supplemental application is supported by encouraging results from the AVA-PED-301 study, which focuses on the use of avatrombopag in treating pediatric patients with immune thrombocytopenia. It's noteworthy that avatrombopag has already received FDA approval for the treatment of thrombocytopenia in adults.
The material has been provided by InstaForex Company - www.instaforex.com
The decision from the FDA, under the Prescription Drug User Fee Act (PDUFA), is anticipated by July 24, 2025. In addition, the FDA has accepted Sobi's New Drug Application (NDA) for an oral suspension form of avatrombopag.
The supplemental application is supported by encouraging results from the AVA-PED-301 study, which focuses on the use of avatrombopag in treating pediatric patients with immune thrombocytopenia. It's noteworthy that avatrombopag has already received FDA approval for the treatment of thrombocytopenia in adults.
The material has been provided by InstaForex Company - www.instaforex.com